Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare limited - propafenone hydrochloride - film-coated tablet - 300 milligram(s) - antiarrhythmics, class ic; propafenone

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare limited - propafenone hydrochloride - film-coated tablet - 150 milligram(s) - antiarrhythmics, class ic; propafenone

Canada - English - Health Canada

sanis health inc - propafenone hydrochloride - tablet - 150mg - propafenone hydrochloride 150mg - class ic antiarrythmics

Canada - English - Health Canada

sanis health inc - propafenone hydrochloride - tablet - 300mg - propafenone hydrochloride 300mg - class ic antiarrythmics

United States - English - NLM (National Library of Medicine)

mckesson corporation dba sky packaging - propafenone hydrochloride (unii: 33xch0hocd) (propafenone - unii:68iqx3t69u) - propafenone hydrochloride 150 mg - propafenone hydrochloride is indicated to: - prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms in patients without structural heart disease. - prolong the time to recurrence of paroxysmal supraventricular tachycardia (psvt) associated with disabling symptoms in patients without structural heart disease. - treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. initiate treatment in the hospital. usage considerations: - the use of propafenone hydrochloride tablets in patients with permanent atrial fibrillation (af) or in patients exclusively with atrial flutter or psvt has not been evaluated. do not use propafenone hydrochloride tablets to control ventricular rate during af. - some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. concomitant treatment with drugs that increase the 

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

hameln pharmaceuticals ltd - sodium chloride - solution for injection - 9mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

hameln pharmaceuticals ltd - sodium chloride - solution for injection - 9mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

hameln pharmaceuticals ltd - sodium chloride - solution for injection - 9mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

hameln pharmaceuticals ltd - sodium chloride - solution for injection - 9mg/1ml

United States - English - NLM (National Library of Medicine)

a-s medication solutions - propafenone hydrochloride (unii: 33xch0hocd) (propafenone - unii:68iqx3t69u) - propafenone hydrochloride 225 mg - propafenone hydrochloride is indicated to: - prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms in patients without structural heart disease. - prolong the time to recurrence of paroxysmal supraventricular tachycardia (psvt) associated with disabling symptoms in patients without structural heart disease. - treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. initiate treatment in the hospital. usage considerations: - the use of propafenone hydrochloride tablets in patients with permanent atrial fibrillation (af) or in patients exclusively with atrial flutter or psvt has not been evaluated. do not use propafenone hydrochloride tablets to control ventricular rate during af. - some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. concomitant treatment with drugs that increase the